| 14.5752 0.075 (0.52%) | 09-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 17.62 | 1-year : | 18.32 |
| Resists | First : | 15.09 | Second : | 15.68 |
| Pivot price | 14.8 |
|||
| Supports | First : | 14.13 | Second : | 11.75 |
| MAs | MA(5) : | 14.55  |
MA(20) : | 14.73 |
| MA(100) : | 16.24 |
MA(250) : | 18.66 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 24.2 |
D(3) : | 24.5 |
| RSI | RSI(14): 43.6 |
|||
| 52-week | High : | 26.51 | Low : | 14.06 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BIS ] has closed above bottom band by 33.8%. Bollinger Bands are 37.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 14.6 - 14.67 | 14.67 - 14.73 |
| Low: | 13.99 - 14.07 | 14.07 - 14.15 |
| Close: | 14.44 - 14.57 | 14.57 - 14.7 |
The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the fund's investment objective. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.
Thu, 12 Sep 2024
Investing Strategies for Market Crashes - Investopedia
Wed, 17 Apr 2024
The 5 Best Healthcare ETFs of 2023 - etf.com
Tue, 14 Nov 2023
5 Best Performing Healthcare ETFs in 2023 - Insider Monkey
Mon, 05 Dec 2022
3 “Oversold” ETFs to Start the Week - ETFdb.com
Wed, 12 Jan 2022
2021 Year in Review: What’s New with the Innovators of the Nasdaq Biotechnology Index? - Nasdaq
Wed, 22 Dec 2021
Top Biotechnology Indexes in the U.S. and How to Invest in Them - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|